APTX News and Press, Aptinyx Inc. From 04/20/22

Preclinical data support the continued clinical development of NYX-783 as a novel mechanistic approach for treating post-traumatic stress disorder (PTSD) NYX-783 is currently under evaluation in a Phase 2b study in patients with PTSD Aptinyx Inc. (Nasdaq: APTX), a cl...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Gainers: Momentus (MNTS) +49%. Trevi Therapeutics (TRVI) +49%. Sunshine Biopharma (SBFM) +34%. Werewolf Therapeutics (HOWL) +30%. System1 (SST) +27%. AppTech Payments (APCX) +22%. MiNK Therapeutics (INKT) +21%. Ikena Oncology (IKNA) +19%. Sprinklr (CXM) +18%. PhaseBio Pharmaceuticals (PHAS) +...

Gainers: Trevi Therapeutics (TRVI) +36%. Sunshine Biopharma (SBFM) +31%. IMAC Holdings (IMAC) +28%. Werewolf Therapeutics (HOWL) +25%. Ikena Oncology (IKNA) +22%. Losers: Aptinyx (APTX) -47%. Vapotherm (VAPO) -29%. Rite Aid (RAD) -23%. Biophytis (BPTS) -13%. Science 37 Holdings (SNC...

The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN). The 229-p...

NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical st...

Shares of Aptinyx Inc. (NASDAQ:APTX) traded at a new 52-week high today of $32.10. Approximately 38 million shares have changed hands today, as compared to an average 30-day volume of 168,000 shares. Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, deve...

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q4 2021 Earnings Call Mar 23, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q4 2021 Earnings Call Transcript

Aptinyx, Inc. (APTX) Q4 2021 Earnings Conference Call March 23, 2022, 05:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development and Investor Relations Andy Kidd - President & CEO Ashish Khanna - CFO & Chief Business Officer Conference Call Participants Ch...

Aptinyx press release (NASDAQ:APTX): Q4 GAAP EPS of -$0.29 beats by $0.05. Cash and cash equivalents were $106.1 million at December 31, 2021. For further details see: Aptinyx GAAP EPS of -$0.29 beats by $0.05